- Home
- Publications
- Publication Search
- Publication Details
Title
Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia
Authors
Keywords
-
Journal
Future Oncology
Volume 9, Issue 8, Pages 1073-1082
Publisher
Future Medicine Ltd
Online
2013-07-31
DOI
10.2217/fon.13.130
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
- (2012) Barbara Scappini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
- (2012) Susan O'Brien et al. BRITISH JOURNAL OF HAEMATOLOGY
- Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
- (2012) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- Current treatment of acute myeloid leukemia
- (2012) Gail J. Roboz CURRENT OPINION IN ONCOLOGY
- Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
- (2012) Jerzy Holowiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
- (2012) Stefan Faderl et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies
- (2012) F J Giles et al. LEUKEMIA
- Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
- (2012) Francis Giles et al. LEUKEMIA RESEARCH
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
- (2011) Stefan Faderl et al. CANCER
- Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia
- (2011) Aine Carol Burke et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
- (2011) Auke D. Adema et al. INVESTIGATIONAL NEW DRUGS
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells
- (2010) A. D. Adema et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression
- (2009) Guilan Jin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
- (2009) Franco Mandelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial
- (2009) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
- (2009) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Nucleoside Transporters: Biomarkers for Response to Nucleoside Drugs
- (2009) Vijaya L. Damaraju et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study
- (2008) Svein Dueland et al. ACTA ONCOLOGICA
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2008) S. Faderl et al. BLOOD
- CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines
- (2008) Carlos M. Galmarini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
- (2008) Thomas Büchner et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells
- (2008) David J. Adams et al. LEUKEMIA & LYMPHOMA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started